Oxaliplatin Accord

Oxaliplatin, the active ingredient in Oxaliplatin Accord, is a platinum‑based chemotherapy agent presented as a sterile solution for intravenous infusion use. It is employed in the treatment of colorectal cancer, often in combination with other cytotoxic drugs, and is administered to adult patients.

GNH USA supplies Oxaliplatin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin Accord is a platinum‑based chemotherapeutic that interferes with DNA replication across several oncologic pathways.

- Colorectal cancer: improves the overall response rate when combined with fluoropyrimidines. - Gastric cancer: used in combination regimens for advanced disease. - Pancreatic cancer: added to multidrug protocols to enhance tumor shrinkage.

Adverse reactions to Oxaliplatin Accord vary in frequency and severity.

Common Side Effects: - Peripheral neuropathy: tingling or c‑ c ‑ c  ​   - Nausea   g   t  "); - Fatigue  - Diarrhea  - Thrombocytopenia  - Elevated liver enzymes 

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis, bronchospasm  - Acute hemolytic anemia  g  g - Nephro‑   t  ");   - Cardiac  ");   - Tumor lysis   - Unexplained death  -  "); -  

The following  g  \n g  

This  g